Cardiovascular toxicities associated with immune checkpoint inhibitors
Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been
reported in case series but have been underappreciated due to their recent emergence …
reported in case series but have been underappreciated due to their recent emergence …
Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology
Recent developments in cancer therapeutics have improved outcomes but have also been
associated with cardiovascular complications. Therapies harnessing the immune system …
associated with cardiovascular complications. Therapies harnessing the immune system …
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma
WD Travis, K Garg, WA Franklin, II Wistuba… - Journal of clinical …, 2005 - ascopubs.org
Purpose To review recent advances in pathology and computed tomography (CT) of lung
adenocarcinoma and bronchioloalveolar carcinoma (BAC). Methods A pathology/CT review …
adenocarcinoma and bronchioloalveolar carcinoma (BAC). Methods A pathology/CT review …
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
JA Engelman, L Chen, X Tan, K Crosby… - Nature medicine, 2008 - nature.com
Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the
p110-α catalytic subunit (encoded by PIK3CA). They are most frequently observed in two …
p110-α catalytic subunit (encoded by PIK3CA). They are most frequently observed in two …
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi… - Oncogene, 2008 - nature.com
Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in
non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with …
non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with …
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
COVID-19, which is caused by SARS-CoV-2, can result in acute respiratory distress
syndrome and multiple organ failure,,–, but little is known about its pathophysiology. Here …
syndrome and multiple organ failure,,–, but little is known about its pathophysiology. Here …
LKB1 modulates lung cancer differentiation and metastasis
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz–
Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of …
Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of …
Persistence and evolution of SARS-CoV-2 in an immunocompromised host
B Choi, MC Choudhary, J Regan… - … England Journal of …, 2020 - Mass Medical Soc
SARS-CoV-2 in an Immunocompromised Host This letter describes an
immunocompromised patient who had persistent infection with SARS-CoV-2 over a period …
immunocompromised patient who had persistent infection with SARS-CoV-2 over a period …
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi, MC Mihm, RJ Soiffer, FG Haluska… - Proceedings of the …, 2003 - pnas.org
A large number of cancer-associated gene products evoke immune recognition, but host
reactions rarely impede disease progression. The weak immunogenicity of nascent tumors …
reactions rarely impede disease progression. The weak immunogenicity of nascent tumors …
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti… - Nature, 2009 - nature.com
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-
mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance …
mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance …